We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Significant Hemolysis Not Required for Thrombosis in PNH

By LabMedica International staff writers
Posted on 19 Mar 2019
Paroxysmal nocturnal hemoglobinuria (PNH), a rare hematological condition, presents with hemolytic or thrombotic symptoms. More...
Cumulative thrombosis incidence in PNH over an eight to ten-year period is 23% to 30%, 20% of patients have multi-site thrombosis and 10% present with thrombosis.

PNH stem cells arise due to somatic mutations in the phosphatidylinositol glycan A (PIGA) gene in bone marrow stem cells, resulting in loss of the glycosylphosphatidylinositol anchor protein (GPI anchor). Loss of this GPI anchor results in absence of CD55 and CD59, complement regulatory proteins on hematopoietic cells, rendering red blood cells susceptible to complement attack and intravascular hemolysis.

Hematologists at St James University Hospital (Leeds, UK) and their colleagues retrospectively interrogated the Leeds (UK) PNH database. Patients with PNH granulocyte or monocyte cell proportions over 10% and an LDH level less than twice the upper limit of normal (ULN) for the testing laboratory were identified. Anonymized clinical data were then analyzed to determine risk factors for thrombosis. Comparisons between those with and without thrombosis were assessed.

A total of 429 patients were analyzed and 25 patients who fit the criteria were identified. Median age of the patient cohort was 60 years (range 23 to 80 years). Eleven patients fit the criteria for group 1 (PNH white cells >30%, PNH red cells <10%, LDH <2×ULN), of whom six (54%) had thrombosis. Eleven patients fit the criteria for group 2, (PNH white cells >30%, PNH red cells >10% with higher proportion of type II red cells than type III red cells, LDH <2×ULN) of whom 2 (18.1%) had thrombosis. Three patients fit the criteria for group 3, (PNH white cells 10%-30%, PNH red cells <10%, LDH <2×ULN) with no thrombosis. Median age at thrombosis was 49 years (range 21-67 years).

Patients at higher risk of presenting with thrombosis were those with high PNH white cell proportions and low PNH red cells (group I). Patients with a greater proportion of type II red cells (partial deficiency of GPI linked proteins) compared to type III red cells (complete deficiency of GPI linked proteins) and LDH <2× ULN were also at risk of thrombosis. This is an under-recognized risk for patients with PNH cells.

The authors concluded that that while hemolysis may be associated with a thrombotic event, white cell and platelet factors appear to have a more pivotal role than previously thought in the mechanisms of thrombosis in PNH. The study was published in the March 2019 issue of the journal Haematologia.

Related Links:
St James University Hospital


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The new RABTA sets a high standard in laboratory diagnostics (Photo courtesy of Randox)

Pioneering Analyzer with Advanced Biochip Technology Sets New Standard in Lab Diagnostics

A state-of-the-art analyzer combines advanced technology with exceptional efficiency to meet the demanding needs of modern laboratories. Randox Toxicology (Antrim, Ireland) has launched its pioneering... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.